UY25084A1 - Un procedimiento para la preparacion de una composicion farmaceutica - Google Patents

Un procedimiento para la preparacion de una composicion farmaceutica

Info

Publication number
UY25084A1
UY25084A1 UY25084A UY25084A UY25084A1 UY 25084 A1 UY25084 A1 UY 25084A1 UY 25084 A UY25084 A UY 25084A UY 25084 A UY25084 A UY 25084A UY 25084 A1 UY25084 A1 UY 25084A1
Authority
UY
Uruguay
Prior art keywords
side chain
free side
peptide
pharmaceutical composition
resin
Prior art date
Application number
UY25084A
Other languages
English (en)
Inventor
Robert Bolin David
O`Donnell Margaret
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of UY25084A1 publication Critical patent/UY25084A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/17—Vasoactive intestinal peptides; related peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/27—Cyclic peptide or cyclic protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Procedimiento para la preparación de una composición farmacéutica cuyo procedimiento comprende mezclar un péptido cíclico, en particular péptidos cíclicos son análogos a los péptidos vasoactivos (VIP); y si se desea, una o más de otras sustancias terapéuticamente activas con un material de vehículo terapéuticamente inerte y dar a la mezcla forma de administración galénica. El procedimiento de preparación de los polipéptidos cíclicos se caracteriza porque: a- un péptido protegido y enlazado a resina de secuencia aminoácido correspondiente se desprotege selectivamente para generar un grupo amino de cadena lateral libre y un grupo carboxilo de cadena lateral libre; b- el grupo amino de cadena lateral libre y el grupo carboxilo de cadena lateral libre se enlazan covalentemente con un reactivo formador de amida apropiado; y c- se desprotege y disocia el péptido ciclado de resina mediante tratamiento con reactivo de desprotección y disociación apropiado. Dichas composiciones son útiles en el tratamiento de trastornos constrictivos broncotraqueales.
UY25084A 1991-10-11 1998-07-06 Un procedimiento para la preparacion de una composicion farmaceutica UY25084A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77374791A 1991-10-11 1991-10-11
UY23488A UY23488A1 (es) 1991-10-11 1992-10-09 Procedimiento para la preparacion de peptidos ciclicos vasoactivos

Publications (1)

Publication Number Publication Date
UY25084A1 true UY25084A1 (es) 1998-12-21

Family

ID=25099195

Family Applications (2)

Application Number Title Priority Date Filing Date
UY23488A UY23488A1 (es) 1991-10-11 1992-10-09 Procedimiento para la preparacion de peptidos ciclicos vasoactivos
UY25084A UY25084A1 (es) 1991-10-11 1998-07-06 Un procedimiento para la preparacion de una composicion farmaceutica

Family Applications Before (1)

Application Number Title Priority Date Filing Date
UY23488A UY23488A1 (es) 1991-10-11 1992-10-09 Procedimiento para la preparacion de peptidos ciclicos vasoactivos

Country Status (26)

Country Link
US (1) US5677419A (es)
EP (1) EP0536741B1 (es)
JP (1) JP2515473B2 (es)
KR (1) KR970001580B1 (es)
CN (3) CN1034943C (es)
AT (1) ATE132165T1 (es)
AU (1) AU656230B2 (es)
BG (1) BG61125B2 (es)
BR (1) BR9203959A (es)
CA (1) CA2080272C (es)
CZ (1) CZ281818B6 (es)
DE (1) DE69207138T2 (es)
DK (1) DK0536741T3 (es)
ES (1) ES2082317T3 (es)
FI (2) FI111646B (es)
GR (1) GR3019326T3 (es)
HU (2) HUT62606A (es)
IL (3) IL103396A (es)
MX (1) MX9205822A (es)
NO (3) NO304523B1 (es)
NZ (1) NZ244644A (es)
RU (1) RU2095368C1 (es)
SK (1) SK279399B6 (es)
TW (1) TW305846B (es)
UY (2) UY23488A1 (es)
ZA (1) ZA927724B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6872803B1 (en) 1993-09-21 2005-03-29 Kyowa Hakko Kogyo Co., Ltd. Peptides
AU722895B2 (en) * 1996-02-09 2000-08-10 F. Hoffmann-La Roche Ag Synthesis of VIP analog
DE69738353T2 (de) 1996-07-12 2009-09-24 Immunomedics, Inc. Radiometall-bindende peptide analoge
WO1998002453A2 (en) * 1996-07-15 1998-01-22 Universite Libre De Bruxelles Peptidic ligands having a higher selectivity for the vip1 receptor than for the vip2 receptor
CA2379604A1 (en) * 1999-09-28 2001-04-05 Bayer Corporation Pituitary adenylate cyclase activating peptide (pacap) receptor 3 (r3) agonists and their pharmacological methods of use
US6972319B1 (en) 1999-09-28 2005-12-06 Bayer Pharmaceuticals Corporation Pituitary adenylate cyclase activating peptide (PACAP)receptor 3 (R3) agonists and their pharmacological methods of use
AU2000263935A1 (en) 2000-02-18 2001-08-27 Dabur Research Foundation Radiolabeled vasoactive intestinal peptide analogs for diagnosis and radiotherapy
WO2001060862A1 (en) 2000-02-18 2001-08-23 Dabur Research Foundation Vasoactive intestinal peptide analogs
US6828304B1 (en) 2000-07-31 2004-12-07 Dabur Research Foundation Peptides for treatment of cancer
US7507714B2 (en) * 2000-09-27 2009-03-24 Bayer Corporation Pituitary adenylate cyclase activating peptide (PACAP) receptor 3 (R3) agonists and their pharmacological methods of use
WO2002043746A2 (en) 2000-11-28 2002-06-06 Mondobiotech Sa Compounds with the biological activity of vasoactive intestinal peptide for the treatment of pulmonary and arteriolar hypertension
CN1313149C (zh) 2002-06-10 2007-05-02 蒙杜生物科技安斯塔特实验室 具有血管活性肠肽的生物学活性的化合物在治疗结节病中的用途
CA2554475A1 (en) * 2004-01-27 2005-08-11 Bayer Pharmaceuticals Corporation Pituitary adenylate cyclase activating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use
WO2006023358A1 (en) * 2004-08-18 2006-03-02 Eli Lilly And Company Selective vpac2 receptor peptide agonists
US20080085860A1 (en) * 2004-08-18 2008-04-10 Eli Lilly And Company Selective Vpac2 Receptor Peptide Agonists
WO2007101146A2 (en) * 2006-02-28 2007-09-07 Eli Lilly And Company Selective vpac2 receptor peptide agonists
CN101484468A (zh) * 2006-07-06 2009-07-15 霍夫曼-拉罗奇有限公司 新型血管活性肠肽类似物
CN101906144B (zh) * 2009-06-03 2013-06-19 首都医科大学 一根Arg-Gly-Asp-Val链通过Asp与两根脂肪醇链的偶联物、它们的合成及在医学中的应用
SG10201407329RA (en) 2009-08-14 2015-01-29 Phasebio Pharmaceuticals Inc Modified vasoactive intestinal peptides
US9782454B2 (en) * 2010-04-22 2017-10-10 Longevity Biotech, Inc. Highly active polypeptides and methods of making and using the same
US9561262B2 (en) 2011-06-06 2017-02-07 Phasebio Pharmaceuticals, Inc. Use of modified vasoactive intestinal peptides in the treatment of hypertension
US9789164B2 (en) 2013-03-15 2017-10-17 Longevity Biotech, Inc. Peptides comprising non-natural amino acids and methods of making and using the same
GB201421647D0 (en) * 2014-12-05 2015-01-21 Amcure Gmbh And Ruprecht-Karls-Universitat And Karlsruher Institut F�R Technologie CD44v6-derived cyclic peptides for treating cancers and angiogenesis related diseases
CN114652817A (zh) 2015-02-09 2022-06-24 费斯生物制药公司 用于治疗肌肉疾病和病症的方法和组合物
KR102243870B1 (ko) 2016-09-30 2021-04-22 후지필름 가부시키가이샤 환상 펩타이드, 어피니티 크로마토그래피 담체, 표지화 항체, 항체 약물 복합체 및 의약 제제

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8427651D0 (en) * 1984-11-01 1984-12-05 Beecham Group Plc Compounds
US4835252A (en) * 1987-02-26 1989-05-30 The Salk Institute Biotechnology/Industrial Associates, Inc. Vasoactive intestinal peptide analogs
GB8729802D0 (en) * 1987-12-22 1988-02-03 Beecham Group Plc Novel compounds
US5084442A (en) * 1988-09-06 1992-01-28 Hoffmann-La Roche Inc. Cyclic growth hormone releasing factor analogs and method for the manufacture thereof
US5141924A (en) * 1989-06-30 1992-08-25 Hoffmann-La Roche, Inc. Synthetic vasoactive intestinal peptide analogs

Also Published As

Publication number Publication date
FI20002041A (fi) 2000-09-15
KR970001580B1 (ko) 1997-02-11
CZ281818B6 (cs) 1997-02-12
EP0536741A3 (es) 1994-04-06
CN1153785A (zh) 1997-07-09
JPH05213996A (ja) 1993-08-24
SK279399B6 (sk) 1998-11-04
ES2082317T3 (es) 1996-03-16
BG61125B2 (bg) 1996-11-29
HU211534A9 (en) 1995-12-28
CA2080272C (en) 2002-09-17
US5677419A (en) 1997-10-14
CN1152579A (zh) 1997-06-25
RU2095368C1 (ru) 1997-11-10
CN1225473C (zh) 2005-11-02
ATE132165T1 (de) 1996-01-15
UY23488A1 (es) 1993-04-20
SK308692A3 (en) 1995-03-08
NZ244644A (en) 1995-04-27
EP0536741A2 (en) 1993-04-14
NO304523B1 (no) 1999-01-04
CA2080272A1 (en) 1993-04-12
HUT62606A (en) 1993-05-28
TW305846B (es) 1997-05-21
NO923929L (no) 1993-04-13
IL103396A (en) 1997-11-20
DE69207138D1 (de) 1996-02-08
CN1198841C (zh) 2005-04-27
FI111646B (fi) 2003-08-29
NO975023D0 (no) 1997-10-31
GR3019326T3 (en) 1996-06-30
CN1034943C (zh) 1997-05-21
KR930007972A (ko) 1993-05-20
IL103396A0 (en) 1993-03-15
AU656230B2 (en) 1995-01-27
FI924580A0 (fi) 1992-10-09
HU9203194D0 (en) 1992-12-28
AU2622892A (en) 1993-04-22
CN1072415A (zh) 1993-05-26
CZ308692A3 (en) 1993-08-11
NO975023L (no) 1993-04-13
NO980377L (no) 1993-04-13
IL117252A0 (en) 1996-06-18
JP2515473B2 (ja) 1996-07-10
DK0536741T3 (da) 1996-04-22
FI924580A (fi) 1993-04-12
DE69207138T2 (de) 1996-06-13
MX9205822A (es) 1993-06-01
EP0536741B1 (en) 1995-12-27
ZA927724B (en) 1994-04-07
NO923929D0 (no) 1992-10-09
IL117252A (en) 1999-11-30
NO980377D0 (no) 1998-01-28
BR9203959A (pt) 1993-04-27

Similar Documents

Publication Publication Date Title
UY25084A1 (es) Un procedimiento para la preparacion de una composicion farmaceutica
KR950702578A (ko) 파라티로이드 호르몬(pth) 및 파라티로이드 호르몬 관련 펩티드(pthrp)의 유사체, 이들의 합성 및 골다공증 치료를 위한 이들의 용도(analogs of pth and pthrp, their synthesis and use for the treatment of osteoporosis)
ES8203385A1 (es) Procedimiento de obtencion de nuevos derivados de la vin- blastina
IL112112A0 (en) Peptide derivatives and pharmaceutical compositions containing them
EP1077070A3 (en) Oral drug delivery compositions
HUP0100705A2 (hu) Hatóanyag-kombinációk alkalmazása, valamint ilyen kombinációkat tartalmazó gyógyszerkészítmények és készletek impotencia kezelésére
AU4009789A (en) Recombinant natural killer cell activator
FR2768341B1 (fr) Composition pharmaceutique placebo lyophilisable destinee a imiter un medicament, notamment a base de proteines ou de polypeptides
KR900001719A (ko) 지질 및 폴리펩티드로 되는 합성 폐 계면활성제의 제조 방법
DK0639225T3 (da) Nye polypeptider og peptider, nucleinsyrer, der koder for dem, og deres anvendelse i området tumorterapi, inflammation eller immunologi
CN1094310A (zh) 人体免疫缺陷性病毒感染用组合式化学疗法
Kenner The Bakerian Lecture-Towards synthesis of proteins
KR950701935A (ko) 항혈소판제로서의 입체배좌적으로 억제된 펩타이드 동족체(Conformationally restrained peptide analogs as antiplatelet agents)
Volterra et al. Interaction of β-casomorphins with multiple opioid receptors: in vitro and in vivo studies in the newborn rat brain
EP0717752A4 (en) THERAPEUTIC COMPOUNDS
FR2694938B1 (fr) Nouveaux peptides, anticorps diriges contre ces peptides, anticorps anti-idiotypiques, application a titre de medicaments, compositions pharmaceutiques et kits de diagnostic les renfermant.
MY104088A (en) Peptide-drugs compositions containing (alpha)-aminoboroic acid derivatives.
AR018532A1 (es) Proteinas sustancialmente puras que contienen analogos de la beta-lipoproteina (blt); aislados de acidos nucleicos que codifican dichas proteinas yformulaciones farmaceuticas que comprenden las proteinas
ITMI982634A1 (it) Composizioni farmaceutiche a base di proteine.
TH35998A (th) Lh-rh เป็ปไทด์ อะนาล็อก ประโยชน์ของสิ่งเหล่านั้นและองค์ประกอบทางเภสัชกรรมซึ่งประกอบด้วยสิ่งเหล่านั้น